The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Clinical outcomes according to ethnicity in patients with metastatic renal cell carcinoma (mRCC) treated with VEGF-targeted therapy (TT).
 
Dominick Bosse
No Relationships to Disclose
 
Wanling Xie
No Relationships to Disclose
 
Connor Wells
No Relationships to Disclose
 
Aly-Khan A. Lalani
No Relationships to Disclose
 
Frede Donskov
Research Funding - GlaxoSmithKline (Inst); Novartis (Inst); Pfizer (Inst)
 
Alisha Bent
No Relationships to Disclose
 
Hao-Wen Sim
No Relationships to Disclose
 
Benoit Beuselinck
No Relationships to Disclose
 
Aristotelis Bamias
Honoraria - Bristol-Myers Squibb; Novartis
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Pfizer; Pierre Fabre
Speakers' Bureau - AstraZeneca; Bristol-Myers Squibb; Novartis; Pfizer
Research Funding - AstraZeneca; Bristol-Myers Squibb; Novartis; Pfizer; Roche; Sanofi
Travel, Accommodations, Expenses - Novartis; Pfizer
 
Camillo Porta
Consulting or Advisory Role - Bristol-Myers Squibb; Eisai; EUSA Pharma; Ipsen; Janssen; Novartis; Peloton Therapeutics; Pfizer
Speakers' Bureau - Bristol-Myers Squibb; Eisai; Ipsen; Novartis; Pfizer
Research Funding - Pfizer (Inst)
 
Ulka N. Vaishampayan
Honoraria - Astellas Pharma; Bayer; Bristol-Myers Squibb; Exelixis; Genentech; Janssen; Novartis; Pfizer; Sanofi
Consulting or Advisory Role - Astellas Pharma; Bayer; Bristol-Myers Squibb; Exelixis; Genentech/Roche; Novartis; Pfizer
Speakers' Bureau - Astellas Pharma; Bayer; Bristol-Myers Squibb; Exelixis; Genentech/Roche; Novartis; Pfizer; Sanofi
Research Funding - Astellas Pharma; Bristol-Myers Squibb; Exelixis; Novartis; Pfizer
 
Sumanta K. Pal
Honoraria - Astellas Pharma; Medivation; Novartis
Consulting or Advisory Role - Astellas Pharma; Aveo; Bristol-Myers Squibb; Exelixis; Genentech; Myriad Pharmaceuticals; Novartis; Pfizer
Research Funding - Medivation
 
Neeraj Agarwal
Consulting or Advisory Role - Argos Therapeutics; Cerulean Pharma; Eisai; EMD Serono; Exelixis; Medivation/Astellas; Merck; Novartis; Pfizer
Research Funding - Amgen (Inst); Bayer (Inst); BN ImmunoTherapeutics (Inst); Bristol-Myers Squibb (Inst); Exelixis (Inst); GlaxoSmithKline (Inst); Medivation (Inst); Novartis (Inst); Pfizer (Inst); Rexahn Pharmaceuticals (Inst); Takeda (Inst); TRACON Pharma (Inst)
 
Sandy Srinivas
Consulting or Advisory Role - Genentech/Roche; medivation; Novartis; pfizer
Speakers' Bureau - Genentech
Research Funding - Bristol-Myers Squibb (Inst); Pfizer (Inst)
 
Brian I. Rini
Consulting or Advisory Role - Pfizer
Research Funding - Bristol-Myers Squibb (Inst); Pfizer (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - Pfizer
 
Ajjai Shivaram Alva
Consulting or Advisory Role - AstraZeneca; Eisai; Roche
Speakers' Bureau - AstraZeneca
Research Funding - Acerta Pharma (Inst); ARIAD (Inst); AstraZeneca (Inst); Bayer (Inst); BIND Biosciences (Inst); BIND Biosciences (Inst); Bristol-Myers Squibb (Inst); Covance (Inst); Genentech (Inst); Hoosier Cancer Research Network (Inst); Merck Sharp & Dohme (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Prometheus (Inst); Roche (Inst); United Biosource Corporation (Inst)
 
Lori Wood
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Exelixis (Inst); GlaxoSmithKline (Inst); Merck (Inst); Pfizer (Inst); Roche Canada (Inst)
 
Anil Kapoor
No Relationships to Disclose
 
Toni K. Choueiri
Honoraria - NCCN; UpToDate
Consulting or Advisory Role - alligent; AstraZeneca; Bayer; Bristol-Myers Squibb; Cerulean Pharma; Eisai; Exelixis; Foundation Medicine; GlaxoSmithKline; Merck; Novartis; Peloton Therapeutics; Pfizer; Prometheus; Roche/Genentech
Research Funding - Agensys (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Celldex (Inst); Exelixis (Inst); GlaxoSmithKline (Inst); Merck (Inst); Novartis (Inst); Peloton Therapeutics (Inst); Pfizer (Inst); Roche/Genentech (Inst); TRACON Pharma (Inst)
Travel, Accommodations, Expenses - advisory boards/consultancy
 
Daniel Yick Chin Heng
Consulting or Advisory Role - Astellas Pharma; Bristol-Myers Squibb; Janssen; Novartis; Pfizer